Flora Growth (FLGC) Projected to Post Earnings on Monday

Key Points

• Flora Growth (NASDAQ:FLGC) is set to release its Q2 2025 earnings results on August 11, with analysts forecasting a loss of ($0.06) per share and revenues of $11.77 million.
• In its last quarterly report on August 1, Flora Growth reported earnings of ($0.11) per share, missing estimates, despite revenues of $14.80 million, which surpassed analyst expectations.
• The company's stock experienced a 12.8% decline during trading, with shares dropping to $17.35 while maintaining a market cap of $391.59 million.

Flora Growth (NASDAQ:FLGC - Get Free Report) is expected to post its Q2 2025 quarterly earnings results before the market opens on Monday, August 11th. Analysts expect Flora Growth to post earnings of ($0.06) per share and revenue of $11.77 million for the quarter.

Flora Growth (NASDAQ:FLGC - Get Free Report) last posted its quarterly earnings results on Friday, August 1st. The company reported ($0.11) earnings per share for the quarter, missing the consensus estimate of ($0.06) by ($0.05). Flora Growth had a negative net margin of 24.86% and a negative return on equity of 250.77%. The firm had revenue of $14.80 million during the quarter, compared to analysts' expectations of $11.77 million. On average, analysts expect Flora Growth to post $-1 EPS for the current fiscal year and $0 EPS for the next fiscal year.

Flora Growth Trading Down 12.8%

Shares of Flora Growth stock traded down $2.54 during mid-day trading on Monday, hitting $17.35. The stock had a trading volume of 10,897 shares, compared to its average volume of 4,915. The firm has a 50-day moving average of $0.65 and a two-hundred day moving average of $0.68. Flora Growth has a 12-month low of $15.15 and a 12-month high of $82.29. The company has a quick ratio of 0.67, a current ratio of 1.05 and a debt-to-equity ratio of 0.88. The firm has a market cap of $391.59 million, a P/E ratio of -19.72 and a beta of 1.97.

Flora Growth Company Profile

Flora Growth Corp., together with its subsidiaries, engages in the growth, cultivation, and development of medicinal cannabis and medicinal cannabis derivative products worldwide. It operates through three segments: House of Brands, Commercial and Wholesale, and Pharmaceuticals. The company cultivates, processes, and supplies medicinal-grade cannabis flower, and cannabis derived medical and wellness products.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.